Bluebird Bio Withdraws Zynteglo From Germany Over Pricing

Germany Is The Only Country Where the Gene Therapy Was Marketed

After arbitrators set an unpalatably low price for the company, bluebird is withdrawing its Zyntgelo gene therapy from Germany. The company also announced it would be restructuring its workforce, with job losses expected.

Bluebird bio
pricing concerns promt bluebird to pull Zynteglo from Germany • Source: Alamy

Price negotiations for bluebird bio’s gene therapy Zynteglo in Germany have failed and the company is withdrawing the high-cost product from the market. Not only is Germany the first country where the one-time gene therapy for treating transfusion-dependent beta-thalassaemia (TDT) was launched, it is also currently the only EU country where the treatment had been given to patients outside of a clinical trial setting.

Zynteglo has not been approved in any other markets worldwide. It is bluebird’s first product and will serve as a sobering lesson for other gene therapy companies that wish to market a gene therapy without the help of big pharma

Zynteglo was first launched in Germany with a freely-set price of €1.575m ($1.88m) in January 2020

More from Europe

More from Geography